普伐他汀对心脏成纤维细胞转化生长因子-β1合成的影响

目的:探讨普伐他汀对醛固酮诱导新生大鼠心脏成纤维细胞转化生长因子-β1(TGF-β1)的影响。方法:采用胰酶消化法和差速贴壁分离法获取和培养心脏成纤维细胞,应用ELISA、Western-blot、RT-PCR的方法分别测定醛固酮、普伐他汀以及甲羟戊酸对心脏成纤维细胞培养液中TGF-β1水平和心脏成纤维细胞TGF-β1mRNA和蛋白质的表达。结果:与正常对照组相比,醛固酮(10-7mol/L)可促进心脏成纤维细胞培养液中TGF-β1水平和心脏成纤维细胞TGFβ-1mRNA和蛋白质的表达,提前给予普伐他汀(10-5,10-4,10-3mol/L)能剂量依赖性地抑制醛固酮的上述作用,同时这种抑制作用可被甲羟戊酸所逆转。结论:普伐他汀可抑制醛固酮诱导的心脏成纤维细胞TGF-β1mRNA表达以及蛋白质的合成和分泌,其机制可能与甲羟戊酸代谢途径有关。     

G蛋白、蛋白激酶C和Na+-H+交换在内皮素-1诱导培养心肌细胞肥大反应中的作用

内皮素-1(ET-1)是一种强的生长因子,并诱导心肌细胞肥大反应.在本实验中,我们探讨了G蛋白、蛋白激酶C(PKC)和Na+-H+交换在ET-1诱导的培养新生大鼠心肌细胞肥大反应中的作用.ET-1(10-10～10-7 mol/L)促进3H-亮氨酸掺入,增加细胞蛋白质的含量和心肌细胞的表面积,且呈剂量依赖性,它们的EC50分别为5.2×10-10,5.2×10-10和7.3×10-10mol/L.用蛋白激酶C(PKC)抑制剂,Staurosporin(2 nmol/L)预处理心肌细胞,可完全阻断ET-1诱导的心肌细胞的这些肥大反应,而蛋白激酶C激动剂,佛波醇酯(PMA)(10-8～10-6mol/L)呈剂量依赖性促进心肌细胞的肥大反应.用Na+-H+交换抑制剂,氨氯吡咪(10-4mol/L)预处理心肌细胞,可抑制ET-1诱导的心肌细胞肥大反应,但不影响PMA诱导的心肌细胞肥大反应.百日咳毒素(150ng/ml)预处理心肌细胞,可明显抑制ET-1诱导的心肌细胞肥大反应.这些结果提示,ET-1诱导的培养新生大鼠心肌细胞肥大反应是与百日咳毒素敏感的G蛋白相耦联,蛋白激酶C和Na+-H+交换可能在ET-1诱导的心肌细胞肥大反应中是重要的细胞内信使转导途径.     

醛固酮对新生大鼠心肌成纤维细胞分泌ET、NO功能的影响

目的: 探讨醛固酮对新生大鼠心肌成纤维细胞(CFs)分泌内皮素(ET)、一氧化氮(NO)的影响.方法: 采用胰酶消化法和差速贴壁分离法获取CFs,应用放射免疫分析法、硝酸还原酶法分别测定不同条件下培养的CFs培养液中的ET、NO水平.结果: 一定浓度范围内的醛固酮可按剂量依赖方式促进CFs分泌ET,抑制CFs分泌NO,使ET/NO比值上升;螺内酯可阻断醛固酮的上述作用(P<0.01).结论: 醛固酮可能通过影响CFs分泌ET、NO,从而改变生物活性物质网络平衡关系,发挥其促心肌纤维化作用.     

奥帕曲拉对内皮素-1诱导的心脏成纤维细胞增殖的影响

目的：探讨奥帕曲拉（omapatrilat,OMA）对内皮素-1（ET-1）诱导的心脏成纤维细胞（CFs）增殖的干预作用及可能机制．方法：经差速贴壁法培养的新生大鼠CFs,随机分为7组：对照组,ET-1组,OMA组,ET-1＋OMA10^-9mol／L组,ET-1＋OMA10^-8mol／L,ET-1＋OMA10^-7mol／L组．ET-1＋OMA10^-6mol／L组.采用四氮唑盐（MTT）比色法测定CFs数目,流式细胞分析仪（FCM）检测CFs细胞周期,液体闪烁计数仪测定CFs^3H-脯氨酸掺入率,硝酸还原酶法测定细胞培养上清液中NO含量：结果：与对照组相比,10^-7mol／LET-1能显著增加CFs的吸光度A190值及[^3H]-Pro掺入率,降低CFs生成NO的量（均P〈0．01）,10^-9-10^-6mol／L OMA呈浓度依赖性的降低ET-1诱导的A190值和[^3H]—Pro掺入率升高（均P〈0．01）,促进CFsNO的生成（均P〈0．05）;细胞周期分析表明ET—1能显著提高S期细胞百分率（P〈0．01）,10^-7mol／LOMA抑制ET-1诱导S期细胞百分率上升（P〈0．01）.结论：OMA对ET-1诱导的CFs增殖及胶原合成有抑制作用,该作用可能和NO生成有关.     

AcSDKP对TGF-β1介导的大鼠心脏成纤维细胞MMP-1、MMP-2和MMP-9表达的调节

目的:探讨N-乙酰基-丝氨酰-天门冬酰-赖氨酰-脯氨酸(AcSDKP)对转化生长因子-β1(TGF-β1)诱导的大鼠心脏成纤维细胞MMP-1、MMP-2和MMP-9调节作用。方法:建立新生大鼠的心脏成纤维细胞系,分别用Westernblot法和明胶酶谱法检测心脏成纤维细胞MMP-1和MMP-2、MMP-9酶的表达。结果:10%血清能使心脏成纤维细胞MMP-2、MMP-9和MMP-1酶的表达增加,AcSDKP能进一步增加在10%血清诱导基础上三种酶的表达。TGF-β1促进心脏成纤维细胞MMP2和MMP-9酶的表达,而下调MMP-1酶表达。AcSDKP能进一步上调由TGF-β1诱导的心脏成纤维细胞MMP2和MMP-9酶的表达,并上调MMP-1酶表达。结论:AcSDKP对TGF-β1诱导的心脏成纤维细胞MMP-2、MMP-9和MMP-1酶表达有促进作用。     

卡托普利对血管平滑肌细胞内皮素基因表达的影响

用反向PCR结合计算机图象处理技术检测卡托普利(CaP)对培养家兔主动脉平滑肌细细内皮素-1(ET-1)mRNA表达的影响。扩增的ET-1cDNA为425bp,经HindⅢ酶切后为279bg和146bg。血管紧张素Ⅱ(Ang-Ⅱ)引起ET-1mRNA表达,诱导表达有时间依赖性(作用3h,表达明显增加,作用5h,表达到高峰,作用7h,表达开始下降)。CaP(1和10μmolL~(-1))明显抑制Ang-Ⅱ引起的ET-1mRNA表达,抑制分别达73％和84％。这些结果表明CaP能直接抑制血管平滑肌细胞的ET—1基因表达。     

NF- kB 对低氧大鼠肺动脉平滑肌细胞ET- 1 表达的影响

目的：探讨核因子kB（NF—kB）对低氧大鼠肺动脉平滑肌细胞（PAMSC）内皮素-1（endothelin—1,ET—1）表达的影响。方法：分离培养大鼠肺动脉平滑肌细胞,分别在常氧和低氧条件下培养48小时。ELISA检测培养上清中ET—1含量,RT—PCR检测ET-1 mRNA表达。在培养液中加入NF—kB抑制剂PDTC,检测PASMCs ET—1表达的变化。Western blotting检测PASMCs IkB表达变化。结果：低氧培养能够诱导PASMCs表达ET—1。NF—kB抑制剂能够减少由于低氧引起的ET—1释放,IkB在低氧情况下表达明显减少。结论：ET-1低氧情况下在PAMCS表达明显增加。可能参与低氧所引起的肺动脉的病理过程。低氧所引起的ET—1表达增加可能通过NF—kB信号通路。     

G蛋白,蛋白激酶C和Na^＋—H^＋交换在内皮素—1诱导培养心肌细胞肥大反应中的

内皮系-1（ET-1）是一种强的生长因子,并诱导心肌细胞肥大反应。在本实验中,我们探讨了G蛋白、蛋白激酶C（PKC）和Na＋－H＋交换在ET-1诱导的培养新生大鼠心肌细胞肥大反应中的作用。ET-1（10－10～10－7mol／L）促进3H－亮氨酸掺入,增加细胞蛋白质的含量和心肌细胞的表面积,且呈剂量依赖性,它们的EC50分别为5．2×10-10,5．2×10－10和7．3×10－10mol／L。用蛋白激酶C（PKC）抑制剂,Staurosporin（2nmol／L）预处理心肌细胞,可完全阻断ET-1诱导的心肌细胞的这些肥大反应,而蛋白激酶C激动剂,佛波酸酯（PMA）（10－8～10－6mol／L）呈剂量依赖性促进心肌细胞的肥大反应。用Na＋－H＋交换抑制剂,氨氯毗咪（10-4mol／L）预处理心肌细胞,可抑制ET－1诱导的心肌细胞肥大反应,但不影响PMA诱导的心肌细胞肥大反应。百日咳毒素（150ng／ml）预处理心肌细胞,可明显抑制ET－1诱导的心肌细胞肥大反应。这些结果提示,ET-1诱导的培养新生大鼠心肌细胞肥大反应是与百日咳毒素敏感的G蛋白相耦联,蛋白激酶C和Na＋．H＋交换可能在ET-1诱导的心肌细胞肥大反应中是重要的细胞内信使转导途径。     

Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats

Endothelin (ET)-1 has been implicated in the development of cardiac hypertrophy. We investigated the effect of pravastatin on development of ventricular hypertrophy in spontaneously hypertensive rats (SHR) and whether the attenuated hypertrophic effect was via reduced ET-1 expression. Normolipidemic SHR were treated with one of the following therapies for 8 wk: vehicle, the nonselective ET receptor antagonists bosentan, pravastatin, mevalonate, hydralazine, or combination of pravastatin + mevalonate from the age of 8 wk at the very early stage of cardiac hypertrophy. Treatment with bosentan and pravastatin significantly decreased left ventricular mass index for body weight and cardiomyocyte sizes isolated by enzymatic dissociation. The myocardial ET-1 levels and preproET-1 mRNA assessed using real-time quantitative RT-PCR were significantly higher (both P < 0.001) in the SHR compared with Wistar-Kyoto rats. The increased tissue ET-1 levels can be inhibited after pravastatin administration. Immunohistochemical analysis confirmed the changes of ET-1. Left ventricular mass index for body weight correlated positively with tissue ET-1 levels (P = 0.0004). A dissociation between the effects of blood pressure and cardiac structure was noted, because pravastatin and hydralazine reduced arterial pressure similarly. Pravastatin-induced effects were reversed by the addition of mevalonate. In conclusion, these results suggest a crucial role of cardiac endothelin system in the early development of ventricular hypertrophy in the SHR. Pravastatin is endowed with cardiac antihypertropic properties that are independent of its hemodynamic and hypolipidemic effects and appear to be related to their capacity to decrease cardiac ET-1 levels, which is linked to mevalonate metabolism.     

醛固酮对心室成纤维细胞分泌内皮素的影响

用细胞培养、内皮素放射免疫测定和RT-PCR的方法,探讨醛固酮对心室成纤维细胞分泌内皮素的影响。结果显示,醛固酮(1×10     

一氧化氮在17-β雌二醇抑制血管平滑肌细胞增殖和原癌基因c -fos表达中的作用

实验利用大鼠血管平滑肌细胞（vascular smooth muscle cells,VSMC)作为模型,观察17-β雌二醇（E2）对VSMC增殖和原癌基因c-fos表达的影响,并探讨VSMC源性一氧化氮（NO）在基中的作用,检测指标包括NO释放的测定,细胞计数、^3H-Tdr掺入,噻唑蓝（MTT）测定和c-fosmRNA表达,结果显示,E2（10^-12-10^-8mol/L)呈浓度依赖性地促进VSMC中NO的释放;10^-8mol/LE2能明显抑制10%小牛血清（FCS）和10^-7mol/L内皮素-1（ET-1）诱导的细胞增殖和DNA合成,E2的抑制作用均可被雌激素受体（ER）拮抗剂tamoxifen(10^-7mol/L)和一氧化氮合酶抑制剂L-NAME（10^-6mol/L)明显减轻;E2（10^-8mol/L)可明显抑制10^-7mol/LET-1诱导的VSMCc-fos表达,这种抑制作用可被L-NAME（10^-6mol/L)明显减轻,这些结果提示E2能抑制VSMC增殖和原癌基因c-fos表达,这种促进VSMC的NO释放密切相关,而且该作用至少部分通过ER介导。     

Cyclooxygenase is regulated by ET-1 and MAPKs in peripheral lung microvascular smooth muscle cells

We examined the hypothesis that the potent vasoconstrictor endothelin (ET)-1 regulates both its own production and production of the vasodilator prostaglandins PGE(2) and prostacyclin in sheep peripheral lung vascular smooth muscle cells (PLVSMC). Confluent layers of PLVSMC were exposed to 10 nM ET-1; expression of the prepro (pp)-ET-1, cyclooxygenase (COX)-1, and COX-2 genes was examined by RT-PCR and Western analysis. Intracellular levels of ET-1 were measured by ELISA with and without addition of the protein synthesis inhibitor brefeldin A (50 microg/ml). Prostaglandin levels were measured by gas chromatography-mass spectrometry. Through use of ET(A) and ET(B) antagonists (BQ-610 and BQ-788, respectively), the contribution of the ET receptors to COX-1 and -2 expression and ppET-1 gene expression was examined. The contribution of phosphorylated p38 and p44/42 MAPK on COX-1 and COX-2 expression was also examined with MAPK inhibitors (p38, SB-203580 and p44/42, PD-98056). ET-1 resulted in transient increases in ppET-1, COX-1, and COX-2 gene and protein expression and release of 6-keto-PGF(1alpha) and PGE(2) (P < 0.05). Both internalization of ET-1 and synthesis of new peptide contributed to an increase in intracellular ET-1 (P < 0.05). Although increased ppET-1 was regulated by both ET(A) and ET(B), COX-2 expression was upregulated only by ET(A); COX-1 expression was unaffected by either antagonist. ET-1 treatment resulted in transient phosphorylation of p38 and p44/42 MAPK; inhibitors of these MAPKs suppressed expression of COX-2 but not COX-1. Our data indicate that local production of ET-1 regulates COX-2 by activation of the ET(A) receptor and phosphorylation of p38 and p44/42 MAPK in PLVSMC.     

Endothelin-1 expression in vascular adventitial fibroblasts

Endothelial cells are a major source of endothelin (ET)-1, but the possibility that vascular adventitial fibroblasts generate ET-1 has not been explored. We hypothesized that aortic adventitial fibroblasts have the ability to produce ET-1, which may contribute to extracellular matrix synthesis. Vascular adventitial fibroblasts were isolated from mouse aorta and incubated with various concentrations of angiotensin II (ANG II). mRNA levels of preproET-1 and type I procollagen were detected with relative RT-PCR. ET-1 levels in culture medium were measured with ELISA. Protein levels of procollagen were detected with Western blotting. ANG II (10 and 100 nM, 1 microM) induced a time- and concentration-dependent increase in preproET-1 mRNA levels (P < 0.05). Induction of preproET-1 mRNA was accompanied by release of immunoreactive peptide ET-1 (P < 0.05). ANG II-evoked increases in preproET-1 mRNA expression and ET-1 release were blocked by losartan (100 microM), an AT1 receptor antagonist, but not PD-123319 (100 microM), an AT2 receptor antagonist. To further confirm our findings, we cloned and then sequenced vascular fibroblast preproET-1 bidirectionally with T7 and M13 reverse sequencing primers. Their nucleotide sequences were identical to preproET-1 cDNA from mouse vascular endothelial cells (accession no. AB081657). Moreover, ANG II-induced type I procollagen mRNA and protein expression were inhibited by BQ-123 (10 microM), an ET(A) receptor inhibitor, but not BQ-788 (10 microM), an ET(B) receptor inhibitor, suggesting a significant role of adventitial ET-1 in regulation of extracellular matrix synthesis. The results demonstrate that vascular adventitial fibroblasts are able to synthesize and release ET-1 in response to ANG II.     

Early activation of cardiac and renal endothelin systems in experimental heart failure

We investigated the time course of the expression of cardiac and renal endothelin systems in tachycardia-induced heart failure in dogs. Eleven beagles underwent rapid pacing at a progressively increased rate over a period of 5 wk, with a weekly clinical examination, echocardiography, measurement of circulating and urinary endothelin-1 (ET-1), and myocardial and renal tissue biopsies. Real-time quantitative PCR was used for determinations of tissue prepro-ET-1 (ppET-1), ET-1-converting enzyme (ECE-1), and ETA and ETB receptor mRNA. Cardiac and renal tissue ET-1 contents were evaluated by immunostaining and measured by radioimmunoassay at autopsy. Rapid pacing caused a progressive increase in end-systolic and end-diastolic ventricular volumes (P < 0.05) from week 2 together with a decrease in ejection fraction and in mean velocity of circumferential shortening (P < 0.05) from week 1. These changes were tightly correlated to myocardial ppET-1 and renal ETA receptor mRNA and less so to myocardial ECE-1 mRNA, and they occurred before any increase in plasma and urinary ET-1 (P < 0.05 from week 4) and clinical signs of heart failure. Renal ppET-1 did not change. Both cardiac and renal ET-1 peptide contents were increased at autopsy. We conclude that tachycardia-induced heart failure in dogs is characterized by an early activation of the cardiac and renal tissue endothelin systems, which occurs before any changes in circulating and urinary ET-1 and is closely related to altered ventricular function.     

Differential effects of different statins on endothelin-1 gene expression and endothelial NOS phosphorylation in porcine aortic endothelial cells

It has been reported that 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitors (statins) produce a variety of cardiovascular protective effects independent of their ability to lower total and low-density lipoprotein cholesterol. Recent studies have also reported that statins produce pleiotropic effects through improved endothelial function, enhanced fibrinolysis, and antithrombotic actions. In the present study, we examined the effects of pitavastatin, pravastatin, atorvastatin, and cerivastatin on endothelin (ET)-1 production in cultured porcine aortic endothelial cells (PAECs). Treatment with cerivastatin but not pitavastatin, pravastatin, or atorvastatin decreased basal and TNF-alpha-stimulated ET-1 release from PAECs in a dose-dependent manner (1-10 microM). Northern blot analysis showed that cerivastatin markedly suppressed prepro ET-1 mRNA expression in both conditions. In addition, these inhibitory effects of cerivastatin on ET-1 release and prepro ET-1 mRNA expression were completely abolished by simultaneous treatment with 200 microM mevalonate. Furthermore, cerivastatin did not have any effects on endothelial nitric oxide synthase (eNOS) protein levels, but induced eNOS phosphorylation at Ser1177. From these findings, it is most likely that cerivastatin suppresses ET-1 production, possibly through an increase in eNOS activity and the subsequent nitric oxide production in PAECs. These findings also suggest that cerivastatin may have beneficial effects on ET-1-related diseases.     

Localization of endothelin receptors in bleomycin-induced pulmonary fibrosis in the rat

Pulmonary fibrosis is characterized by excessive extracellular matrix deposition with concomitant loss of gas exchange units, and endothelin-1 (ET-1) has been implicated in its pathogenesis. Increased levels of ET-1 from tissues and bronchoalveolar lavage have been reported in patients with pulmonary fibrosis and in animal models after intratracheal bleomycin. We characterized the cellular distribution of alveolar ET receptors by immunohistochemistry in bleomycin-induced pulmonary fibrosis in the rat and determined the regulation by bleomycin of ET receptor mRNA expression in isolated alveolar macrophages and rat lung fibroblasts. We found significant increases in the numbers of fibroblasts and macrophages at day 7 compared to day 28 and control animals. ET(B) receptor immunoreactivity was observed on fibroblasts and invading monocytes. Isolated fibroblasts expressed both ET(A) and ET(B) receptor mRNA, and ET(A) receptor mRNA was upregulated by bleomycin. Isolated resident alveolar macrophages expressed neither ET(A) nor ET(B) receptor mRNA which were also not induced by bleomycin. We conclude that, while ET(B) receptor stimulation of fibroblasts and monocytes recruited during bleomycin-induced lung injury exerts antagonistic effects on fibroblast collagen synthesis, the observed increase in the number of fibroblasts in vivo and upregulation of fibroblast ET(A) receptor mRNA by bleomycin in vitro point to a predominance of the profibrotic effects of ET receptor engagement.     

Profibrotic effects of endothelin-1 via the ETA receptor in cultured human cardiac fibroblasts.

BACKGROUND/AIMS: Endothelin-1 (ET-1) has been implicated in pathologic remodelling and tissue repair processes in the heart. We investigated the effects of ET-1 on growth and collagen synthesis responses in cardiac fibroblasts isolated from human hearts. We also studied the receptor subtype(s) mediating such responses and the factors regulating their expression. METHODS: Fibroblasts were isolated from cardiac transplant recipient hearts and characterised by immunocytochemistry. Serum-starved cells were exposed to ET-1 and incorporation of [3H]proline and thymidine were measured as indexes of collagen and DNA synthesis respectively. Blocking experiments utilised the selective ETA receptor antagonist BQ123 and the ETB antagonist BQ788. RESULTS: ET-1 elicited a potent collagen synthesis response in cardiac fibroblasts, with a maximum 29+/-5% increase that was abolished by BQ123. Cardiac fibroblasts responded to ET-1 with a concentration-dependent decrease in DNA synthesis rate. The effects of ET-1 were similar to those of TGF-beta. Radioligand binding studies revealed the presence of high-affinity ET-1 binding sites on these cells, which were upregulated by treatment with the growth factors PDGF and EGF but downregulated by TGF-beta. CONCLUSIONS: These results therefore implicate ET-1 as a trophic agent in the human heart with the ability to influence the development of cardiac fibrosis.